Phesi Market Research Report

Company Overview

• Name: Phesi

• Mission: Accelerate drug development and commercialization through precise trial protocol design and flawless execution across all phases of development and indications, facilitating life sciences companies in delivering novel therapies to patients faster and at a reduced cost.

• Founded: 2007

• Founder: Dr. Gen Li

• Key People:

• Dr. Gen Li, PHD, MBA - President & Founder

• Jonathan Peachey - Chief Operations Officer

• Paul Chew, MD - Chief Medical Officer

• Guoqiang Wu - Chief Information Officer

• Headquarters: No information is available.

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Phesi is known for its AI-driven data platform and services which accelerate clinical development and enable precision medicine for all disease areas using the world's largest clinical trials database.

Products

• Trial Accelerator Platform:

• Description: A solution that accelerates the design and execution of patient-centric trials, leveraging a vast database of real-world data.

• Key Features:

• Predictive modeling capabilities in various views such as Patient Profile, Trial Performance, Country, and Investigator Site.

• Integration with digital twin and digital trial arm services to generate reliable evidence without traditional trial overhead.

• Protocol Design Optimization:

• Description: Utilizes model design value simulation to prevent costly trial failures and protocol amendments.

• Key Features: Enhances the trial design process by integrating comprehensive data analytics to predict and optimize outcomes.

• Digital Twin & Digital Trial Arm:

• Description: A service that models diseases and patient outcomes using digital profiles and real-world data.

• Key Features: Provides reliable evidence generation, mimicking actual patient scenarios without the need for extensive traditional trials.

Recent Developments

• New Products Launched:

• Investigator Site Profile Solution, launched in September 2024. This self-service solution is designed to eliminate non-active and non-enrolling investigator sites, enhancing trial site selection accuracy.

• Awards:

• In September 2024, Phesi was awarded the Frost & Sullivan’s Global Enabling Technology Leadership Award for their revolutionary Trial Accelerator Platform.

• Publications:

• A new Phesi Nature publication in July 2024 demonstrated the potential of AI-powered digital twins to replace external control arms in clinical trials.

• Partnerships:

• No specific new partnerships mentioned.

• Additional Features:

• Launch of the predictive Patient Burden Score in May 2024 aimed at improving trial efficiency, patient experience, and investigator site performance.

• Analytics:

• Recent analysis indicates a 50% increase in global oncology trial investigator sites over a five-year period according to June 2024 data.

• Analysis published in January 2025 points out that breast cancer remains the most studied disease for the fourth year consecutively despite a rising trial attrition rate.

Phesi's comprehensive suite of tools and services offers significant enhancements to the field of biopharmaceutical clinical trials, utilizing data-driven methodologies to streamline processes and improve outcomes across various therapeutic areas.